New application of tilolife in treatment of serious fatigue
Tilorixen, a histamine H3-receptor antagonist, effectively treats severe fatigue in patients with narcolepsy and other neurological disorders by improving psychometric measures of fatigue, distinguishing it from excessive daytime sleepiness.
Patent Information
- Application Number
- CN202380035782.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-23
- Filing Date
- 2023-03-21
- Publication Date
- 2024-12-03
AI Technical Summary
There are no effective pharmacological treatments for severe fatigue (SF) in patients with narcolepsy or other neurological disorders, despite its significant clinical consequences such as functional impairment and decreased quality of life.
Administering tilorixen, a histamine H3-receptor antagonist, at doses between 50 mg and 240 mg once daily to treat severe fatigue in patients with disorders associated with SF, particularly narcolepsy.
Tilorixen effectively improves severe fatigue as measured by psychometric tests like the flicker fusion test, with higher doses showing significant improvement without adverse effects, addressing the distinct nature of fatigue from excessive daytime sleepiness.
Smart Images

Figure BDA0005097520650000031 
Figure HDA0005097520660000011
Abstract
Description
[0001] The present invention relates to therapeutic treatment of severe fatigue.
[0002] Severe fatigue (SF) is defined as the subjective experience of mental or physical exhaustion that does not disappear after a period of sleep (Vercoulen et al. J. Psychosom. Res. 1994, 38, 383-392).
[0003] SF has been found in a high proportion of patients with chronic neurological disorders, such as Parkinson's disease (Friedman et al., Mov. Disorder, 2007, 22, 297-308), multiple sclerosis (van der Werf et al., J. Neurol. Sci., 1998, 160, 164-170) and neuromuscular disorders (Kalkman et al., J. Psychosom. Res., 2007, 62, 571-579). In these diseases, severe fatigue has been shown to have important clinical consequences, such as increased functional limitations and decreased overall health status (Kalkman et al., J. Neurol. Neurosurg. Psychiatry, 2005, 76, 1406-1409).
[0004] SF may also be associated with narcolepsy.
[0005] The core symptoms of narcolepsy include excessive daytime sleepiness (EDS) and cataplexy. EDS is defined as the inability to stay awake and alert during the main wakeful hours of the day, resulting in inadvertent drowsiness and / or sleep (Droogleever Fortuyn et al. J. Sleep Res. 21, 2, 2012, 163-169).
[0006] Although patients may have difficulty distinguishing daytime sleepiness and sleep attacks from physical fatigue, excessive daytime sleepiness and fatigue are distinct symptoms that have been shown to co-occur independently in patients with sleep disorders (Lichstein et al. Behav. Res. Ther. 1997, 35, 733-740; Merkelbach et al. J Sleep Res. 2006 Mar; 15(1): 105-6).
[0007] Droogleever Fortuyn et al., 2011 also reported that SF is very common in patients with narcolepsy, but it should be distinguished from EDS.
[0008] Therefore, treatment of EDS may not necessarily improve SF status.
[0009] For example, a meta-analysis of clinical trials of the psychostimulant modafinil in various neurological disorders concluded that the drug was generally effective for EDS, but had no significant effect on fatigue (Sheng et al. PLoS One. 2013 Dec 3;8(12):e81802).
[0010] Similar conclusions were reached in trials in traumatic brain injury (Kaiser et al. Neurology. 2010 Nov 16;75(20):1780-5).
[0011] Taken together, a wealth of data suggests that, although SF and EDS commonly coexist in several neurological disorders, they are distinct pathological manifestations.
[0012] In a recent validation study of the Fatigue Severity Scale (FSS), one of the most commonly used fatigue scales, in a cohort of 429 patients with sleep-wake disorders, Valko et al. Sleep, 2008, 31, 1601-1607 showed that a subgroup of narcolepsy patients had the highest fatigue scores.
[0013] Droogleever Fortuyn et al., 2011 determined the prevalence of SF and its association with excessive daytime sleepiness, psychological distress, functional impairment, and quality of life in a group of 80 patients diagnosed with narcolepsy with cataplexy. Fatigue was measured using the Checklist Individual Strength questionnaire (CIS). In addition, psychological distress, including symptoms of depression, functional impairment, and quality of life were assessed. In this group of patients, more than 60% of the patients were found to show SF. There were no age or gender differences between patients with and without EF.
[0014] Importantly, both fatigued and non-fatigued patients had the same amount of daytime sleepiness (Epworth sleepiness score 14.3±4.2 vs. 13.1±4.4, P=0.22), confirming the distinction between sleepiness and fatigue. Severe fatigue was associated with significantly increased functional impairment, increased depressive symptoms, and decreased overall quality of life.
[0015] In summary, most patients with narcolepsy suffer from severe fatigue that can be distinguished from daytime sleepiness and leads to significant functional impairment.
[0016] Despite numerous trials, no clear evidence has emerged so far for the pharmacological treatment of SF in narcolepsy or even in other neurological pathologies.
[0017] For example, in a recent Cochrane meta-analysis of SF in cancer and other chronic diseases, Mücke et al. (Cochrane Database Syst Rev. 2015(5):CD006788.doi:10.1002 / 14651858.CD006788.pub3.PMID:26026155; PMCID:PMC6483317) concluded: "Based on limited evidence, we cannot recommend specific medications for the treatment of fatigue. Research on fatigue in palliative care appears to focus on modafinil and methylphenidate, which may be beneficial in the treatment of fatigue associated with palliative care, although further research on their efficacy is needed."
[0018] As another example, Nourbakhsh et al. (Lancet Neurol. 2021, 20(1):38-48) conducted a large double-blind placebo-controlled trial of amantadine, modafinil, and methylphenidate for SF in multiple sclerosis and concluded that "Amantadine, modafinil, and methylphenidate are not superior to placebo in improving fatigue in multiple sclerosis and cause more frequent adverse events. The results of this study do not support the indiscriminate use of amantadine, modafinil, or methylphenidate for the treatment of fatigue in multiple sclerosis."
[0019] Thus, it appears that commonly used wakefulness-promoting agents, which are often used to promote wakefulness and reduce EDS, are ineffective for treating SF. In particular, there are no treatments indicated for SF in patients with narcolepsy, nor for other neurological conditions where evidence for efficacy of treatments is also lacking.
[0020] It is therefore desirable to provide new, effective candidates for the treatment of SF.
[0021] Pitolisant (3-(4-chlorophenyl)propyl 3-piperidinylpropyl ether) has the following chemical formula:
[0022]
[0023] It is a novel histamine H3-receptor antagonist that triggers an enhanced release of brain histamine. Histamine is known to be a major wakefulness-promoting neural system (Schwartz et al. Physiol Rev. 1991 Jan;71(1):1-51).
[0024] The use of tilorixan for the treatment of sleep and vigilance disorders such as EDS associated with Parkinson's disease, obstructive sleep apnea, narcolepsy, dementia with Lewy bodies and / or vascular dementia is disclosed in WO 2006 / 103546.
[0025] Tilosin monohydrochloride has been licensed in Europe and the United States and is marketed under the trade name Wakix, among others, as a drug for the treatment of narcolepsy in adults with or without cataplexy, and excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy. It represents the first commercially available drug in the class of histamine H3-receptor antagonists / inverse agonists. The recommended dose for the treatment of narcolepsy and / or EDS is 10 to 40 mg once daily (od).
[0026] This dose is consistent with studies reporting high occupancy of brain histamine H3-receptors at a dose of 40 mg tilorixen hydrochloride (Rusjan PBr J Pharmacol. 2020 Aug;177(15):3464-3472).
[0027] Tilolisen monohydrochloride at doses of 20 to 40 mg once daily (od) has been shown to improve EDS and cataplexy in patients with narcolepsy, but its effect on SF has never been evaluated in these patients with narcolepsy.
[0028] In patients with obstructive sleep apnea (OSA), 20 mg od of tilorexan monohydrochloride reduced EDS in two trials, while SF assessed by the Pichot scale was statistically different from placebo in one trial (Dauvilliers Y et al. Am J Respir Crit Care Med. 2020 May 1; 201(9): 1135-1145), but not in another trial (Pepin et al. Chest 2021, 159(4), 1598-1609). This further confirms that fatigue and EDS are different entities that respond differentially to treatment, and the conclusion that the use of tilorexan for the treatment of fatigue in patients with OSA has not been established so far.
[0029] Additionally, the activity of tilorixan in fatigue associated with other conditions has not been reported.
[0030] In a trial conducted by the applicant, it was found that tilorixan at a dose of 30 mg did not improve fatigue in volunteers who were sleep deprived during a 24 h period.
[0031] Therefore, the effect of tilolisan on fatigue is very unclear.
[0032] It would therefore be desirable to provide new treatments for fatigue, particularly fatigue associated with narcolepsy or other disorders.
[0033] Tilolisen has been identified as being active against fatigue, particularly in patients with narcolepsy.
[0034] More particularly, tilolisan has been found to be effective at high doses without adverse effects.
[0035] According to a first aspect, the present invention provides tilorexan for use in the treatment and / or prevention of severe fatigue (SF), comprising administering once daily in patients suffering from disorders associated with SF a dose of between 50 mg and 240 mg of tilorexan or one of the following: a pharmaceutically acceptable salt, hydrate or hydrated salt thereof, or a polymorphic crystal structure of these compounds or their optical isomers, racemates, diastereomers or enantiomers.
[0036] As used hereinafter, "tilorixan" also includes its pharmaceutically acceptable salts, hydrates or hydrated salts, or polymorphic crystal structures of these compounds or their optical isomers, racemates, diastereomers or enantiomers.
[0037] As used herein, the terms "severe fatigue", "SF", "excessive fatigue" or "fatigue" are used interchangeably. It refers to a condition characterized by mental or physical exhaustion that does not disappear after a period of sleep (Vercoulen et al. J. Psychosom. Res. 1994, 38, 383-392).
[0038] There are no available animal models for fatigue.
[0039] In humans, SF can be measured using a variety of tests such as the Pichot Fatigue Scale, the Personal Fatigue Intensity Questionnaire (CIS), or the Flicker Fusion Test.
[0040] The CIS is a validated measure with good internal consistency and international acceptance. This test can be used to assess SF severity using the Fatigue Severity Scale (FSS), with a score range of 8-56. In this scale, the population mean is around 16, and the cut-off value for SF is 35 points (Vercoulen et al., 1994; Droogleever Fortuyn et al., 2011).
[0041] The flicker fusion frequency (FFF) is defined as the frequency, in units of flickers per second, at which intermittent light appears as a steady light. It has been determined that the score achieved in such a test can be used as a measure of fatigue (Luczak A, et al. Ergonomics, 2005 Dec 15; 48(15): 1770-92; Ma et al. PLoS One, 2014 Feb 5; 9(2): e87121; Maeda et al. Jpn J Radiol. 2011 Aug; 29(7): 483-7).
[0042] The activity of tilorexant in SF can be assessed by its ability to improve the score in any of the above tests, preferably in the flicker fusion test.
[0043] As used herein, "pharmaceutically acceptable salts" refer to derivatives of tilorixan that are modified by preparing their acid or base salts. Pharmaceutically acceptable salts include conventional non-toxic salts or quaternary ammonium salts of tilorixan, for example, formed from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, aminosulfonic acid, phosphoric acid, nitric acid, etc.; and salts prepared from organic acids such as acetic acid, propionic acid, succinic acid, tartaric acid, citric acid, methanesulfonic acid, benzenesulfonic acid, glucuronic acid, glutamic acid, benzoic acid, salicylic acid, toluenesulfonic acid, oxalic acid, fumaric acid, maleic acid, etc. Additional addition salts include ammonium salts such as tromethamine salts, meglumine salts, 1-pyrrolidineethanol (epolamine) salts, etc., and metal salts such as sodium salts, potassium salts, calcium salts, zinc salts, or magnesium salts. Hydrochlorides and oxalates are preferred.
[0044] The pharmaceutically acceptable salts of the present invention can be synthesized from tilorixen by conventional chemical methods. Typically, such salts can be prepared by reacting the free acid or base form of tilorixen with a stoichiometric amount of an appropriate base or acid in water or in an organic solvent or in a mixture of the two. Typically, non-aqueous media such as ether, ethyl acetate, ethanol, isopropanol or acetonitrile are preferred. A list of suitable salts is found in Remington's Pharmaceutical Sciences, 17th edition, Mack Publishing Company, Easton, PA, 1985, page 1418, the disclosure of which is incorporated herein by reference.
[0045] The monohydrochloride salt of tilolixan is preferred.
[0046] According to a further object, the present invention relates to a method for the treatment and / or prevention of severe fatigue (SF), which method comprises administering once daily in a patient in need thereof suffering from a disorder associated with SF, a dose comprised between 60 mg and 240 mg of tilorixen or one of the following: a pharmaceutically acceptable salt, hydrate or hydrated salt thereof, or a polymorphic crystal structure of these compounds or their optical isomers, racemates, diastereomers or enantiomers.
[0047] In general, the determination of those subjects who need treatment for the diseases and conditions described herein is well within the ability and knowledge of those skilled in the art. Clinicians skilled in the art can easily determine subjects who need such treatment by using clinical tests, physical examinations, genetic tests, and medical / family history.
[0048] According to one embodiment, the patient suffers from narcolepsy, obstructive sleep apnea (OSA), multiple sclerosis, Parkinson's disease, cancer, depression, bipolar disorder, post-stroke disorder, post-COVID disorder, chronic fatigue syndrome, fibromyalgia, traumatic brain injury, inflammatory bowel disease.
[0049] According to certain embodiments, the patient does not suffer from OSA.
[0050] According to more specific embodiments, the patient suffers from narcolepsy, such as narcolepsy associated with cataplexy or narcolepsy without cataplexy.
[0051] According to the present invention, the once daily administration dose between 50 mg and 240 mg refers to the actual dose of tilorixen (ie) in the base form, while tilorixen or its pharmaceutically acceptable salt, hydrate, or hydrated salt, or any one of its polymorphic crystals may be administered.
[0052] According to one embodiment, the recommended dosage of tilorixen may be comprised between 50 and 120 mg and preferably between 60 and 120 mg.
[0053] It will also be understood that the dosage ranges are for adult patients and that equivalent dosages in human children can be adjusted accordingly.
[0054] Administration is performed once daily (od), preferably in the morning. According to one embodiment, tilorixan is administered after waking up, before breakfast.
[0055] Adjustments in dosage and / or administration time can be readily determined by the attending diagnostician, who is a person skilled in the art, by using conventional techniques and by observing the results obtained under similar circumstances. In determining a therapeutically effective amount, the attending diagnostician considers many factors, including, but not limited to: the species of the subject; its size, age, and general health; the specific disease involved; the extent or severity of the disease; the response of the individual subject; the specific compound administered; the mode of administration; the bioavailability characteristics of the administered formulation; the selected dosage regimen; the use of concomitant medications; and other relevant circumstances. The amount of tilorixen required to achieve the desired biological effect will vary according to many factors, including the dose of the drug administered, the chemical characteristics of the compound used (e.g., hydrophobicity), the potency of the compound, the type of disease, the patient's disease state, and the route of administration.
[0056] "Pharmaceutically" or "pharmaceutically acceptable" refers to molecular entities and compositions that do not produce an adverse, allergic, or other undesirable reaction when administered to an animal or a human, where appropriate.
[0057] In the context of the present invention, the terms "treat" or "treatment" as used herein means to reverse, alleviate, inhibit the progression of, or prevent the disorder or condition to which such terms apply, or one or more symptoms of such disorder or condition.
[0058] "Therapeutically effective amount" refers to an amount of a compound / drug according to the present invention effective to produce the desired therapeutic effect.
[0059] According to the present invention, the term "patient" or "patient in need thereof" refers to a human or non-human mammal who is affected by or is likely to be affected by a neuropsychological disorder. Preferably, the patient is a human.
[0060] Generally, tilorixan may be provided in a pharmaceutical composition with one or more pharmaceutically acceptable excipients.
[0061] As used herein, "pharmaceutically acceptable excipients" include any diluent, adjuvant or vehicle, such as preservatives, fillers, disintegrants, wetting agents, emulsifiers, suspending agents, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, etc. The use of such media and agents for pharmaceutically active substances is well known in the art. Unless any conventional media or agents are incompatible with the active ingredient, they are considered for use in therapeutic compositions. Supplementary active ingredients can also be incorporated into the composition.
[0062] According to one embodiment, tilorexan can be administered in a unit dose form, wherein the term "unit dose" refers to a single dose that can be administered to a patient and which can be easily handled and packaged to maintain a physically and chemically stable unit dose, the unit dose containing tilorexan itself, or as a pharmaceutically acceptable composition, as described below.
[0063] Tilolisan can be formulated into a pharmaceutical composition by mixing with one or more pharmaceutically acceptable excipients.
[0064] The compositions may conveniently be administered in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy, for example, as described in Remington: The Science and Practice of Pharmacy, 20th ed.; Gennaro, AR, ed.; Lippincott Williams & Wilkins: Philadelphia, PA, 2000. Pharmaceutically compatible binding agents, and / or adjuvant materials may be included as part of the composition.
[0065] According to one embodiment, tilolisan is suitable for oral administration, in particular in the form of a tablet.
[0066] Tablets and the like may contain any of the following ingredients or compounds of a similar nature: binders such as microcrystalline cellulose or tragacanth; diluents such as starch or lactose; disintegrants such as starch and cellulose derivatives; lubricants such as magnesium stearate; glidants such as colloidal silicon dioxide; sweeteners such as sucrose or saccharin; or flavoring agents such as mint or methyl salicylate. In addition, dosage unit forms may contain various other materials which modify the physical form of the dosage unit, for example, coatings of sugar, shellac, or enteric agents. Oral dosage forms such as syrups or elixirs may contain sweeteners, preservatives, dyes, colorants, and flavoring agents.
[0067] Preferred formulations include pharmaceutical compositions wherein tilorixan is formulated for oral administration, and more preferably formulated as tablets. Oral compositions will generally include an inert diluent carrier or an edible carrier. Preferred tablets contain lactose, corn starch, magnesium silicate, croscarmellose sodium, povidone, magnesium stearate or talc in any combination.
[0068] Attached photos:
[0069] Figure 1 The absolute differences in flicker fusion thresholds (post-treatment-pre-treatment) for treatment groups (control or tilolexan monohydrochloride at 20, 40 or 60 mg) are shown (* indicates significant changes 1.5 or 11 h after treatment with tilolexan). Example
[0070] 1. Critical Flicker Fusion Test (CFFT) in Healthy Volunteers
[0071] In human healthy volunteers, fatigue can be assessed at the end of the day (when fatigue tends to increase) using known psychometric tests such as the flicker fusion test reported by Luczak A, et al. Ergonomics, 2005 Dec 15;48(15):1770-92; Ma et al. PLoS One, 2014 Feb 5;9(2):e87121; Maeda et al. Jpn J Radiol. 2011 Aug;29(7):483-7.
[0072] In a group of 36 healthy volunteers, changes in fusion frequency were evaluated at several times of the day and after administration of placebo or tilorixen monohydrochloride at increasing doses (20, 40 or 60 mg). Fusion frequency was altered especially at the end of the day, when tilorixen monohydrochloride reversed the changes when given orally at a dose of 60 mg, whereas lower doses did not provide significant changes (see Figure 1 ).
[0073] In contrast, in the same group of subjects, arousal was assessed by analyzing their spectral EEG and was found to have been significantly improved at a dose of 40 mg tilorixen monohydrochloride (not shown).
[0074] This suggests that wakefulness is more sensitive to tilorexam than fatigue, and that higher doses are required to achieve significant improvement in fatigue.
[0075] 2. In sleep-deprived subjects
[0076] Tilolisen monohydrochloride was administered once daily at a dose of 30 mg in human volunteers who were sleep deprived during a 24 h period. Fatigue assessed by fusion frequency in these volunteers was not altered by placebo or tiloresen at this dose.
[0077] in conclusion
[0078] Thus, treatment with 30 to 40 mg of tilorixen monohydrochloride did not appear to improve the flicker fusion test, which is known to improve EDS in patients with narcolepsy at these doses.
[0079] In contrast, when tilorixen monohydrochloride was administered at 60 mg to fatigued healthy volunteers, flicker fusion testing significantly improved.
[0080] 3. Adverse reactions
[0081] It was found that tilolisan could be used at doses up to 240 mg od without significant adverse effects.
[0082] A group of 24 healthy volunteers received placebo or tilorexan monohydrochloride at a dose of 160, 200 or 240 mg. This last dose is equivalent to 6 times the maximum dose recommended in narcolepsy. Blood samples for analysis of tilorexan and metabolite levels showed a dose proportional relationship. The number and nature of adverse events did not differ between tilorexan-treated and placebo-treated subjects.
[0083] No significant abnormalities were recorded for laboratory parameters, vital signs, physical examinations, and ECG parameters. In addition, few abnormalities were reported in all treatment groups.
[0084] Considering these results, it can be concluded that tilolisan administered at 160 mg, 200 mg and 240 mg is safe and well tolerated.
[0085] 4. Brain histamine H3 receptor occupancy
[0086] Six healthy volunteers received 40 mg of tilorexan monohydrochloride. A PET scan study was performed. The authors reported that therapeutic doses of tilorexan occupied a large portion of the histamine H3 receptors (84 ± 7% (mean ± SD)) (Rusjan PBr J Pharmacol. 2020 Aug; 177(15): 3464-3472) and suggested that based on this high occupancy, activity of tilorexan in various CNS disorders associated with H3 receptors could be expected at this therapeutic dose.
[0087] This is consistent with the significant effects of tilorixen at this therapeutic dose on EDS and cataplexy in patients with narcolepsy.
[0088] Therefore, the lack of improvement on the flicker fusion test was unexpected at this dose of tiloresen, which is known to improve EDS in patients with narcolepsy.
[0089] Furthermore, it would not be expected that a higher threshold dose of tilorixen hydrochloride than that at which high occupancy was achieved would be required to improve SF.
Claims
1. Tilolisen for use in the treatment and / or prevention of severe fatigue (SF), comprising administering once daily in patients suffering from disorders associated with SF a dose of between 50 mg and 240 mg of Tilolisen or one of the following: a pharmaceutically acceptable salt, hydrate or hydrated salt thereof, or a polymorphic crystal structure of these compounds or their optical isomers, racemates, diastereomers or enantiomers.
2. Tilolexan for use according to claim 1, wherein Tilolexan is administered in a dose comprised between 50 mg and 120 mg.
3. Tilosin for use according to any one of the preceding claims, wherein the patient suffers from narcolepsy, obstructive sleep apnea, multiple sclerosis, Parkinson's disease, cancer, depression, bipolar disorder, post-stroke disorder, post-COVID disorder, chronic fatigue syndrome, fibromyalgia, traumatic brain injury, inflammatory bowel disease.
4. Tirolexan for use according to any one of the preceding claims, wherein the patient suffers from narcolepsy.
5. Tirolesen for use according to claim 4, wherein the patient suffers from narcolepsy associated with cataplexy.
6. Tirolexan for use according to claim 4, wherein the patient suffers from narcolepsy without cataplexy.
7. Tilolisan for use according to any one of the preceding claims, wherein the salt is the monohydrochloride salt.
